Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
46.05
USD
|
+1.32%
|
|
+5.28%
|
+29.32%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
777.7
|
1,403
|
1,840
|
1,244
|
1,699
|
2,224
|
-
|
-
|
Enterprise Value (EV)
1 |
777.7
|
1,403
|
1,840
|
1,244
|
1,699
|
2,224
|
2,224
|
2,224
|
P/E ratio
|
-79.1
x
|
515
x
|
-246
x
|
-75.3
x
|
-509
x
|
576
x
|
94.6
x
|
52.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
6.6
x
|
11.3
x
|
11.8
x
|
7.57
x
|
8.6
x
|
9.3
x
|
7.43
x
|
5.87
x
|
EV / Revenue
|
6.6
x
|
11.3
x
|
11.8
x
|
7.57
x
|
8.6
x
|
9.3
x
|
7.43
x
|
5.87
x
|
EV / EBITDA
|
-81.8
x
|
75.5
x
|
62.4
x
|
51.4
x
|
50.2
x
|
45.8
x
|
29.7
x
|
25.5
x
|
EV / FCF
|
-79,363,660
x
|
93,860,642
x
|
-
|
123,263,648
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
0%
|
-
|
0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
44,695
|
45,429
|
46,815
|
47,223
|
47,725
|
48,290
|
-
|
-
|
Reference price
2 |
17.40
|
30.88
|
39.30
|
26.34
|
35.61
|
46.05
|
46.05
|
46.05
|
Announcement Date
|
2/25/20
|
2/24/21
|
2/24/22
|
2/23/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
117.8
|
124.2
|
156.2
|
164.4
|
197.5
|
239.2
|
299.2
|
379.1
|
EBITDA
1 |
-9.507
|
18.58
|
29.48
|
24.2
|
33.88
|
48.5
|
74.87
|
87.1
|
EBIT
1 |
-11.25
|
2.372
|
-7.854
|
-17.06
|
-6.464
|
5.361
|
27.21
|
47.95
|
Operating Margin
|
-9.55%
|
1.91%
|
-5.03%
|
-10.38%
|
-3.27%
|
2.24%
|
9.1%
|
12.65%
|
Earnings before Tax (EBT)
1 |
-9.665
|
3.044
|
-7.582
|
-15.99
|
-2.368
|
6.723
|
28.66
|
48.08
|
Net income
1 |
-9.665
|
2.864
|
-7.471
|
-16.71
|
-3.182
|
4.268
|
25.45
|
46.62
|
Net margin
|
-8.2%
|
2.31%
|
-4.78%
|
-10.17%
|
-1.61%
|
1.78%
|
8.51%
|
12.3%
|
EPS
2 |
-0.2200
|
0.0600
|
-0.1600
|
-0.3500
|
-0.0700
|
0.0800
|
0.4867
|
0.8725
|
Free Cash Flow
|
-9.799
|
14.95
|
-
|
10.09
|
-
|
-
|
-
|
-
|
FCF margin
|
-8.31%
|
12.04%
|
-
|
6.14%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
80.42%
|
-
|
41.7%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
521.86%
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/20
|
2/24/21
|
2/24/22
|
2/23/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
34.51
|
47.59
|
36.07
|
37.05
|
38.55
|
52.69
|
41.02
|
45.92
|
45.58
|
65
|
49.07
|
54.33
|
57.02
|
78.82
|
60.3
|
EBITDA
1 |
4.301
|
12.77
|
3.243
|
2.772
|
3.325
|
14.86
|
1.7
|
4.441
|
5.444
|
22.3
|
4.742
|
7.165
|
8.488
|
28.11
|
11.15
|
EBIT
1 |
-4.961
|
4.141
|
-7.273
|
-9.082
|
-6.788
|
6.085
|
-8.177
|
-5.961
|
-5.057
|
12.73
|
-5.495
|
-2.678
|
-1.486
|
15.02
|
-0.2467
|
Operating Margin
|
-14.38%
|
8.7%
|
-20.16%
|
-24.52%
|
-17.61%
|
11.55%
|
-19.94%
|
-12.98%
|
-11.09%
|
19.59%
|
-11.2%
|
-4.93%
|
-2.61%
|
19.06%
|
-0.41%
|
Earnings before Tax (EBT)
1 |
-4.931
|
4.209
|
-7.091
|
-8.963
|
-6.556
|
6.622
|
-7.495
|
-5.02
|
-3.946
|
14.09
|
-5.172
|
-2.331
|
-1.14
|
15.37
|
0.0867
|
Net income
1 |
-4.931
|
4.535
|
-7.091
|
-8.963
|
-6.577
|
5.922
|
-7.495
|
-5.02
|
-3.66
|
12.99
|
-5.33
|
-2.654
|
-1.067
|
13.32
|
-0.08
|
Net margin
|
-14.29%
|
9.53%
|
-19.66%
|
-24.19%
|
-17.06%
|
11.24%
|
-18.27%
|
-10.93%
|
-8.03%
|
19.99%
|
-10.86%
|
-4.89%
|
-1.87%
|
16.9%
|
-0.13%
|
EPS
2 |
-0.1100
|
0.0900
|
-0.1500
|
-0.1900
|
-0.1400
|
0.1300
|
-0.1600
|
-0.1100
|
-0.0800
|
0.2600
|
-0.1100
|
-0.0567
|
-0.0217
|
0.2583
|
-0.0320
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/21
|
2/24/22
|
5/4/22
|
8/3/22
|
11/9/22
|
2/23/23
|
5/10/23
|
8/2/23
|
11/8/23
|
2/29/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-9.8
|
14.9
|
-
|
10.1
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
2.33%
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
1.6%
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
179.4
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
2.63
|
-
|
7.6
|
20
|
16
|
10
|
-
|
Capex / Sales
|
-
|
2.11%
|
-
|
4.62%
|
10.13%
|
6.69%
|
3.34%
|
-
|
Announcement Date
|
2/25/20
|
2/24/21
|
2/24/22
|
2/23/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
46.05
USD Average target price
53.9
USD Spread / Average Target +17.05% Consensus |
1st Jan change
|
Capi.
|
---|
| +29.32% | 2.22B | | -4.66% | 86.13B | | +1.32% | 39.82B | | -19.27% | 30.42B | | +57.86% | 25.23B | | -17.69% | 11.6B | | -43.00% | 11.51B | | -9.14% | 11.95B | | +5.24% | 8.71B | | -8.42% | 8.12B |
Biopharmaceuticals
|